Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (2021)
80 slides from Coloplast A/s Class B's roadshow presentation, 2021
Slide 1: Roadshow presentation 9M 2020/21: Making life easier
Roadshow presentation 9M 2020/21 Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP ‘I love taking my boat out and I do so whenever I can. Sometimes the weather stops me. But I won’t let my condition stop me.’ Flemming Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Int
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Q3 organic growth of 11% and EBIT margin of 33%; guidance narrowed
Q3 organic growth of 11% and EBIT margin of 33% – financial guidance for FY 2020/21 narrowed REVENUE GROWTH Q3 Highlights Reported revenue (mDKK) +3% • Organic growth of 11% and 9% reported growth in DKK Organic growth • Organic growth rates by business area: Ostomy Care 4%, Continence Care 5%, +6%
Slide 4: Significant progress across the Clinical Performance Program
We have made significant progress across the Clinical Performance Program Status October 2020 Status June 2021 Expected launch Product launch Digital ostomy - CE mark has been granted expected in first solution Pilot studies conducted with successful results ✓ - Payer pilot studies in Germany and th
Slide 5: Q3 growth driven by Interventional Urology recovery
Q3 growth was driven by a recovery in Interventional Urology led by Men’s Health and improving underlying growth in Europe Q3 20/21 revenue by business area Q3 20/21 revenue by geography Business Reported revenue Q3 Organic growth Share of organic Geographic Reported revenue Q3 Organic growth Share
Slide 6: Ostomy Care grew 4% in Q3
Ostomy Care grew 4% in Q3 driven by improving underlying growth in Europe, partly offset by the US and tender phasing in EM Ostomy Care performance Q3 Highlights • Q3 organic growth of 4% and 2% reported growth 6 • Growth was driven by improving underlying growth in Europe, partly offset 4 4 4 by th
Slide 7: Continence Care grew 5% in Q3
Continence Care grew 5% in Q3 driven by improving underlying growth in Europe, partly offset by negative COVID-19 impact in the US Continence Care performance Q3 Highlights • Q3 organic growth of 5% and 4% reported growth • Growth was driven by improving underlying growth in Europe, partly offset by
Slide 8: Interventional Urology grew 82% in Q3
Interventional Urology grew 82% in Q3 driven by a broad-based recovery led by US Men’s Health and a low baseline Interventional Urology performance Q3 Highlights • Q3 organic growth of 82% and 73% reported growth 82 • Interventional Urology growth was driven by a broad-based recovery in elective pro
Slide 9: Wound & Skin Care grew 17% in Q3
Wound & Skin Care grew 17% in Q3, and Wound Care alone grew 20% driven by Europe and China Wound & Skin Care performance Q3 Highlights • Q3 organic growth of 17% and 14% reported growth 20 • Wound Care in isolation grew 20% driven by Europe and China, as well as a lower baseline 17 9 • Growth in Eur
Slide 10: Q3 reported growth up 9%, below organic growth
Q3 reported growth was up 9%, 2%-points below organic growth due to depreciation of the USD and Emerging markets currencies Revenue development (DKKm) Q3 Highlights • Reported revenue increased by DKK 416 million, or 9% compared to Q3 2019/20 • Q3 organic growth was 11% or DKK 499 million 499 9 -92
Slide 11: Reported EBIT margin of 33% in Q3
Reported EBIT margin of 33% in Q3 reflecting efficiency gains and lower costs due to COVID-19, partly offset by commercial investments EBIT margin development (%) Q3 Highlights • Q3 gross margin was 69%, against 67% in Q3 last year 0.3 33.2 0.4 32.9 • Positive impact from leverage, Global Operations
Slide 12: FCF driven by solid underlying development in earnings
FCF driven by solid underlying development in earnings FCF development Comments Highlights • Free cash flow for 9M 2020/21 was DKK 1,626 million compared to DKK 2,436 million in 9M 2019/20 98 99 98 93 • Adjusting for acquisitions, mainly Nine Continents Medical, the free 90 91 cash flow for 9M 2020/
Slide 13: Organic growth guidance for FY 2020/21 narrowed
Organic growth guidance for FY 2020/21 narrowed GUIDANCE 2020/21 GUIDANCE 2020/21 (DKK)* KEY ASSUMPTIONS • Double-digit growth in the second half of 2020/21 SALES Lower end of 7-8% Unchanged 4-5% • Continued resumption of elective procedures and hospital activity across business range range areas as
Slide 14: Introduction to Coloplast
Making it easier Stina to be yourself LEADING INTIMATE HEALTHCARE Introduction to Coloplast
Slide 15: Four business areas with global sales presence
Coloplast has four business areas all with global sales presence Group revenue 2019/20 by segment Group revenue 2019/20 by geography 1 Continence Care European 1 37% markets 58% Ostomy Care Other developed 40% markets DKK DKK 25% 18.5bn 18.5bn 4 5 Interventional Emerging Urology Wound & Skin Care 10
Slide 16: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs WHO ARE OUR TYPICAL USERS HOW DO WE HELP THEM? People who have had their intestine redirected to an SenSura® Mio Ostomy Care opening in the abdominal wall Ostomy bag People in need of bladder or bowel management SpeediCath® Continence Flexible male
Slide 17: Chronic Care model secures predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKKbn) Organic growth (%) 10 10 9 8 8 8 8 7 7 7 7
Slide 18: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Surgical and medical trends Growing elderly population Earlier detection and cure, increases customer base for eventually reduces addressable Coloplast products market for Coloplast treatment Limiters Drivers product
Slide 19: Strong market positions in Europe and potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Ostomy Continence Urology Wound Care Emerging Addressable market 18 - 19bn 14 - 15bn 11 - 12bn 22 - 24bn Size in DKK 4 - 5% 5 - 6% 3 - 5% 2 - 4% Growth in %* Coloplast 40 - 50% 45 - 5
Slide 20: Building the consumer healthcare company of the future
We are building the consumer healthcare company of the future MACRO TRENDS IMPACT COMMERCIAL MODEL Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer preference Data and Clinical digital tools preference Price pressure Payer preferen
Slide 21: New strategy drives long-term value creation
Our new strategy will drive continued long-term value creation through revenue and earnings growth Chronic Care Interventional Wound & Urology Skin Care 7-9% more than30% organic growth p.a. EBIT margin1 Talent, Innovation Leadership & Culture Unparalleled Sustainability efficiency 1) Constant curre
Slide 22: Supporting sustainable development and environmental performance
Supporting sustainable development with a strong emphasis on improving our environmental performance Our mission Making life easier for people with intimate healthcare needs Stina Our 2025 priority Our 2025 priority Improving Reducing products and emissions packaging 80% packaging made from renewabl
Slide 23: Yearly incremental investments of up to 2% of revenue
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue Key Investment Decision Drivers Key Investment Areas Economics & We expect to invest up to 2% Innovation of revenue in incremental OPEX investments Government Market Chronic Care Attractiveness U
Slide 24: Actively pursue M&A opportunities
We will actively pursue M&A opportunities as a lever for long-term growth Opportunity Systematic screening based Portfolio Channel Early stage Large plays expansion & expansion technologies adjacencies Page 24
Slide 25: Key enablers supporting the Chronic Care commercial model
We have built key enablers to support the commercial model in our Chronic Care businesses COMMERCIAL MODEL KEY ENABLERS Direct Businesses Superior, clinically differentiated products Coloplast Consumer Care Consumer Clinical preference Data and digital tools preference Direct to Consumer Payer prefe
Slide 26: Direct business in Chronic Care drives growth
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Care presence Control and continuity of 1 product supply ~30% MS ~15% MS ~5% MS +30 countries 2 Target the full value p
Slide 27: Clinical Performance Program tackles biggest user issues
We have initiated a very ambitious Clinical Performance Program to tackle the biggest issues users face What really matters to people using catheters? What really matters to people living with a stoma? of users describe UTIs are their 45 %* 93 % worry about leakage2 greatest challenge in life1 * Peo
Slide 28: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional investments within distribution and R&D Gross Profit development, % Cost item Development, in % of revenue +0.6%-points 28.1 28.7 29.0 28.7 28.1 28-30 Distribution -0.1%-points 68.1 67.3 67.7 68.0 68.4 +0.1%-points 4.0 4
Slide 29: Automation, procurement and scale in Global Operations
Automation, procurement and scale are key to bringing Global Operations to the next level 1. Automation to mitigate growth in blue-collar FTE 10% ~800 >1,000 DKK ~450m # of FTE release ~500 CAPEX investment over ~200 through automation four years (19/20 – 22/23) Salary1 (Direct labour) 19/20 20/21 2
Slide 30: Global Business Support and IT landscape
A global Business Support and IT landscape enables Coloplast to scale faster and more efficiently Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance / accounting Master Data Labelling (Chronic
Slide 31: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Future drivers of EBIT margin ILLUSTRATIVE EBIT will be positively impacted by: Leverage effect on fixed costs e.g. distribution, admin and >30% R&D costs especially dri
Slide 32: Continued strong free cash flow during Strive25
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX(2) Reported tax rate Depreciation in % of revenue CAPEX DKKm Net working capital in % revenue CAPEX in % of revenue 5% 6% 5% 4% 4% 4% 5% 4% 4% 4% 4% 26% 4% 23% 23% 23% 23% 23% ~23% 2
Slide 33: Attractive cash returns despite large investments
We will continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Highlights Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) • Coloplast returns excess liquidity to share
Slide 34: Stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin development Highlights 33% • Stable market trends in our Chronic Care business 10% 6% • Strong Coloplast Care retention program 9% and innovative DtC activities 06/07 08/09 10/1
Slide 35: Appendices
Tabitha Leading intimate healthcare LEADING INTIMATE HEALTHCARE Appendices
Slide 36: The Coloplast share (COLO-B.CO)
The Coloplast share (COLO-B.CO) Coloplast share listed on Nasdaq Copenhagen since 1983 Share Capital Ownership ~242 billion DKK (~38 billion USD) market cap @ ~1,138 DKK 10% per share (incl. A shares) 6% 2% Two share classes: 45% • 18m A shares carry 10 votes (family) • 198m B shares carry 1 vote (f
Slide 37: Capital structure
Capital structure Comments Net interest bearing debt • Overall policy is that excess liquidity is 0.7x returned to shareholders through a 3,606 combination of dividends and share buy- 0.1x 0.1x 0.1x 0.2x backs • Interest bearing debt will be raised in connection with a major acquisition or other spe
Slide 38: 9M 2020/21 revenue by business area and geography
9M 2020/21 growth driven by solid IU recovery in the US and Ostomy Care in Emerging markets 9M 20/21 revenue by business area 9M 20/21 revenue by geography Reported revenue 9M Organic growth Share of organic Geographic Reported revenue 9M Organic growth Share of organic Business DKKm 9M growth area
Slide 39: 9M reported revenue up 3%
9M 2020/21 reported revenue was up 3%, impacted by depreciation in the USD, GBP and Emerging market currencies 9M Revenue development (DKKm) Highlights • 9M 2020/21 reported revenue increased by DKK 372 million compared to 9M 2019/20 840 12 -481 • 9M organic growth was 6% or DKK 840 million 14,326 •
Slide 40: 9M reported EBIT margin of 33%
9M 2020/21 reported EBIT margin of 33% driven by efficiency gains and lower commercial spending due to COVID-19 9M EBIT margin development (%) Highlights • 9M gross margin was 68%, on par with last year 33.4 • Positive impact from leverage on production costs and 0.3 0.0 0.1 32.8 efficiency gains fr
Slide 41: Key Value Ratios
Key Value Ratios Profitability drivers Free Cash Flow drivers 36.3 36.2 37.0 31.9 32.7 32.3 34.7 34.6 32.0 31.6 28.7 29.0 28.1 28.7 28.1 25.2 25.8 23.4 23.6 23.4 4.0 4.0 4.2 4.1 3.8 4.4 4.1 5.0 5.1 3.5 3.7 3.9 3.9 3.8 3.8 16/17 17/18 18/19 19/20 YTD 20/21 16/17 17/18 18/19 19/20 YTD 20/21 Admin-to-S
Slide 42: Revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology 7 8 6 5 9 22 6 7 5 2 13 16 6 7,166 7,538 10 10 6,291 6,643 6 8 9 5,783 10 10 7 5 6 -7 1,641 1,740 1,970 1,835 1,573 16/17 17/18 18/19 19/20 YTD 20/21 16/17 17/18 18/19 19/20 YTD 20/21 Continence Care Wound & Skin Care
Slide 43: Revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 5 6 6 2 3 2 5 6 2 2 15 16 10,573 10,820 11 9 9,394 9,941 8 11 8,349 4 5 6 2 3,791 4,380 4,644 3,642 3,500 16/17 17/18 18/19 19/20 YTD 20/21 16/17(1) 17/18 18/19 19/20 YTD 20/21 Emerging Markets Coloplast group 7 8 9
Slide 44: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Chronic Care Interventional Urology Wound & Skin Care Ostomy and Continence Care 59 57 60 60 59 25 41 46 43 37 41 42 42 42 40 2,193 2,200 2,156 244 2,092 2,011 214 269 199 200 238 239 252 230 79 Q3 19/20 Q4 19/20 Q1 20/21 Q2 20/21 Q3 20/
Slide 45: Exchange rate exposure and hedging policy
Exchange rate exposure FY 2020/21 and hedging policy Revenue FX exposure 2020/21(1) 12 months exposure from 10% initial exchange rate drop(1) Other 17% -410 USD -170 EUR 36% -280 CNY, JPY, AUD, BRL & ARS 13% GBP -190 HUF 0 100 14% GBP 20% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 46: US Mesh litigation: overview of financial impact
US Mesh litigation – Overview of financial impact P&L Balance Cash flow Assets Actual/Expected cash flow, DKKbn 13/14 14/15 15/16 16/17 17/18 18/19 19/20 20/21 Restricted cash, DKKbn 0.5 0.5 EBIT (before special items) 4,147 4,535 4,846 5,024 5,091 5,556 5,854 4,705 Special items -1,000 -3,000 - 750
Slide 47: Stable global health reforms environment
Stable global health reforms environment Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • U.S.: Reimbursement pressure on OC and CC (Managed Care) • France: Reimbursement pressure on WC Reimbursement pressure Page 47
Slide 48: CARE increases retention and product compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 49: DtC marketing program reaches into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our service …and with the reach we get several benefits and product offering… Expose innovative products Ensure product accessibility Ensure successful experience Page 49
Slide 50: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance $ Product Page 50
Slide 51: Interventional Urology revenue balanced geographically
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance ~15% market share in global market of DKK 12-13bn market FY 18/19 growing 3-5% annually 11% Coloplast position, FY 18/19 Endourology Men’s Health Women’s Health Bladder H
Slide 52: Interventional Urology split into four business areas
Coloplast Interventional Urology is split into four business areas MEN’S WOMEN’S SPECIALTY ENDOUROLOGY HEALTH HEALTH INTERVENTIONS • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Tes
Slide 53: Strong presence with room to capture market share
We have a strong presence in our categories but there is room to capture market share Coloplast Share Competitive Share Men’s Health Women’s Health Endourology1 Bladder Health & Surgery1 <5% 30-35% <5% 35-45% 35-45% 10-15% 15-20% Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) in
Slide 54: Coloplast acquires Nine Continents Medical
Coloplast acquires Nine Continents Medical Inc, an early stage company in the large over-active bladder segment Over-active bladder market Company and product description • Over-active bladder (OAB) is a condition that causes a frequent and • Nine Continents Medical Inc is an early stage company pio
Slide 55: Global Advanced Wound Care market remains large and growing
The global Advanced Wound Care market remains large and growing despite a challenging 19/20 The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and is expected to grow despite the pandemic categories and grow faster than the market Ma
Slide 56: Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 57: US Ostomy Care innovation drives growth
In US Ostomy Care, innovation is the biggest growth driver and we continue to win across patient pathway We have gained significant share over the last Innovation is a key driver, and we will continue to expand our offering years of high-quality products Bags & Plates acute share SenSura® Mio portfo
Slide 58: Awarded access to Vizient and Premier GPOs
Coloplast has been awarded access to Vizient and Premier GPOs, ensuring a level playing field in ~75% of acute accounts Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute Estimated Contract start Contract Contract members1 Acute share2 date length type 3,6
Slide 59: Sustainability: key priorities and actions
Sustainability - key priorities and actions Improving products and packaging Reducing emissions Responsible operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products As a growing company, we are challenged Our people and cult
Slide 60: Q3 2020/21 progress on sustainability ambitions
Q3 2020/21 progress on key sustainability ambitions1) Improving products and packaging Reducing emissions Responsible operations 2025 Q3 FY 2025 Q3 FY 2025 Q3 FY Ambition 20/21 19/20 Ambition 20/21 19/20 Ambition 20/21 19/20 80% 6% 6% 100% 100% 98% Renewable 70% 70% White-collars Scope 1+2 material
Slide 61: 2025 priority: Reducing emissions
Our 2025 priority: Reducing emissions We are committed to reducing emissions while being a growth company 2025 target – Scope 1+2 Other 0 Emissions from production Energy 7% 100% Renewable energy (PPAs and phase out 6% natural gas use) 13% 2025 target – Scope 3 Our Transport of goods 5% Limit on goo
Slide 62: Introducing Ostomy Care
Introducing Ostomy Care Disease areas Key products Distribution of • Colorectal cancer (est. 45%) revenues* • Bladder cancer (est. 10%) • Diverticulitis (est. 15%) Urostomy • Inflammatory bowel disease (est. 10%) Ileostomy • Other (est. 20%) Colostomy Customer groups • Nurses, mainly stoma care nurs
Slide 63: Introducing Ostomy Care Supporting Products
Introducing Ostomy Care Supporting Products Market fundamentals Key products • Market size of DKK ~3bn • Market growth of 6-8% • Market share 35-40% Brava® Protective Seal Brava® Skin Barrier • Main competitors include: Hollister • Designed for leakage • Reducing skin problems Adapt, ConvaTec, 3M Ca
Slide 64: Introducing Continence Care
Introducing Continence Care Disease areas Key products Distribution of • Spinal Cord Injured, SCI revenues • Spina Bifida, SB • Multiple Sclerosis, MS Intermittent catheters • Benign prostatic hyperplasia, BPH & prostatectomy patients Urine bags • Elderly Male ext. catheters Bowel management CC Othe
Slide 65: Introducing Bowel Management
Introducing Bowel Management Disease areas Market dynamics Peristeen® Plus Anal Irrigation Faecal incontinence Launched in 2021 + Growing awareness (management products only) + Huge underpenetrated and Customer groups unserved population • Spinal Cord Injured, SCI + New devices addressing the many •
Slide 66: Introducing Interventional Urology
Introducing Interventional Urology Surgical treatment of urological disorders Disease areas Key products Distribution of revenues • Urinary incontinence • Pelvic organ prolapse Men’s health • Erectile dysfunction Women’s health • Enlarged prostate • Kidney and urinary stones Single use devices Custo
Slide 67: Introducing Wound Care
Introducing Wound Care Disease areas Key products Distribution of revenues Chronic wounds (WSC) • Leg ulcers Biatain® range • Diabetic foot ulcers Comfeel® range • Pressure ulcers Skin Care Customer groups Wound Care other Contract manufacturing & call points Hospitals Biatain® Silicone Non-Border B
Slide 68: Introducing Skin Care
Introducing Skin Care Disease areas Key products Product mix • Moisture associated skin damage Protectants & Antifungals • Incontinence Cleansing/Bathing • Skin folds & obesity Moisturizers • Prevention of skin impairments Textile SC Other Customer groups & call points Sween® EasiCleanse Bath® Hospi
Slide 69: Product market for US Skin Care
Product market for US Skin Care Market drivers/limiters US Skin Care at a glance + Aging and obese population • US market size estimated at DKK + CMS Value Based Purchasing 4-5bn with 2-4% growth + Increased focus on prevention + Increased importance of utilization • Market share: 10-15% management
Slide 70: The Coloplast organisation
The Coloplast organisation Coloplast Group Chronic Care Strategic Business Units Chronic Care Strategic Business Units Ostomy Care Continence Care Wound & Skin Care Interventional Urology R&D Marketing Sales R&D Marketing Marketing Operations Sales Regions Global Operations Global Business Support F
Slide 71: Coloplast Executive Leadership Team
Coloplast Executive Leadership Team Kristian Villumsen President, CEO • Born 1970 • With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Camilla G. Møhl Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations • Born 1969 • Born 1972
Slide 72: Income statement
Income statement DKKm Q3 2019/20 Q3 2020/21 Change 9M 2019/20 9M 2020/21 Change Revenue 4,419 4,835 9% 13,954 14,326 3% Gross profit 2,970 3,335 12% 9,452 9,792 4% SG&A costs -1,426 -1,585 11% -4,563 -4,580 0% R&D costs -182 -185 2% -533 -548 3% Other operating income/expenses 6 27 350% 26 41 58% Op
Slide 73: Balance sheet
Balance sheet DKKm 30 Jun 2020 30 Jun 2021 Change Balance, total 13,315 15,458 16% Assets Non-current assets 6,825 8,631 26% Current assets 6,490 6,827 5% of which: Inventories 2,116 2,378 12% Trade receivables 2,997 3,142 5% Amounts held in escrow 12 - nm Marketable securities, cash, and cash equiv
Slide 74: Cash flow
Cash flow DKKm 9M 2019/20 9M 2020/21 Change EBIT 4,382 4,505 3% Depreciation and amortisation 636 601 -6% Change in working capital -497 -421 -15% Net interest payments -156 -16 -90% Paid tax -1,190 -1,413 19% Other -103 80 -178% Cash flow from operations 3,072 3,336 9% Investment in intangibles1) -
Slide 75: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 4% Hungary 11% 0% 2% Mørdrup Tatabánya China Minneapolis Sarlat Nyirbátor US/France Mankato Denmark Zhuhai Costa Rica Costa Rica 83% COGS by cost type² 10% 18% Salary - Direct 12% Salary - Indirect 8% Materials (RM &SFG) Innovation & Specialised Pr
Slide 76: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~900 • Number of employees in production: ~1,800 T
Slide 77: Production sites
Production sites Denmark US Mørdrup Minneapolis • Pilot development work Ostomy care, • Interventional Urology products Continence care and Wound care • Number of employees in production: ~100 • Adhesives production • Number of employees in production: ~150 France Sarlat Mankato • Disposable surgica
Slide 78: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 79: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Ellen Bjurgert Aleksandra Dimovska Hannah Katrine Larsen Otto Munk Madsen Vice President, Investor Relations Senior Manager, Investor Relations Investor Relations Coordinator & PA Student Assistant, Investor Relations Tel. direct: +45 49
Slide 80: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /